...

Emergent to make Providence Therapeutics potential COVID-19 vaccine




  • In US
  • 2021-09-14 12:14:50Z
  • By Reuters
 

(Reuters) -Emergent BioSolutions Inc signed a five-year agreement with Canadian biotechnology company Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate for about $90 million.

Emergent will produce drug substances for Providence's vaccine candidate, PTX-COVID19-B, as well as provide services for finished products such as filling the vaccine in vials at its Winnipeg facility in Canada.

The vaccine uses the messenger RNA (mRNA) technology, also used in COVID-19 shots developed by Moderna Inc and Pfizer Inc. Providence's vaccine is currently being tested in a mid-stage trial in Canada.

Emergent expects to manufacture tens of millions of doses of Providence's shot in 2022, as well as batches of formulated bulk drug substance for the vaccine with the potential to yield hundreds of millions more doses.

The agreement covers cost for manufacturing services, studies to support global supply chain activities, as well as facility and equipment investments, the companies said on Tuesday.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

COMMENTS

More Related News

What you need to know about the coronavirus right now
What you need to know about the coronavirus right now
  • US
  • 2021-09-23 12:39:18Z

French vaccine maker Valneva is expanding trials of a COVID-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a...

Valneva expands trials on COVID-19 vaccine candidate
Valneva expands trials on COVID-19 vaccine candidate
  • US
  • 2021-09-23 05:11:39Z

PARIS (Reuters) -French vaccine maker Valneva is expanding trials of a COVID-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a potential contract, the company said on Thursday. Valneva shares plunged 42% after Britain said on Sept 13 that it cancelled its contract for about 100 million doses of the vaccine the company is developing, partly over concerns about when it would win approval for use.. "Valneva continues discussions with the European Commission regarding a potential VLA2001 supply contract," the company said in a statement.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US